The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Prakhova L.N.

N. Bechtereva Institute of the Human Brain

Krasnov V.S.

Pavlov First St. Petersburg State Medical University

Kasatkin D.S.

Yaroslavl State Medical University

Korobko D.S.

State Novosibirsk Regional Clinical Hospital;
Novosibirsk State Medical University

Local experience of IL-6 pathway inhibition with satralizumab for patients with neuromyelitis optica spectrum disorder

Authors:

Prakhova L.N., Krasnov V.S., Kasatkin D.S., Korobko D.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7‑2): 68‑72

DOI: 10.17116/jnevro202212207268

Read: 4020 times

Download PDF (RU)
Contact the author
Table of contents

LOCAL EXPERIENCE OF IL-6 PATHWAY INHIBITION WITH SATRALIZUMAB FOR PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER
LOCAL EXPERIENCE OF IL-6 PATHWAY INHIBITION WITH SATRALIZUMAB FOR PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER

To cite this article:

Prakhova LN, Krasnov VS, Kasatkin DS, Korobko DS. Local experience of IL-6 pathway inhibition with satralizumab for patients with neuromyelitis optica spectrum disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7‑2):68‑72. (In Russ.)
https://doi.org/10.17116/jnevro202212207268

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Satralizumab is a monoclonal anti-IL6-anibody for patients with neuromyelitis optica or neuromyelitis optica spectrum disorder (NMOSD) seropositive for anti-AQP4-antibody. Satralizumab has been approved in 2021 in the Russian Federation for usage in adults and adolescents from 12 years and older in combination with basic therapy or in monotherapy. The efficacy and safety of satralizumab in comparison with placebo have been demonstrated in two international randomized clinical trials SakuraStar and SakuraSky, phase III. We present clinical experience with satralizumab gained in frames of the Compassionate Use Program that have been initiated in Russia for NMOSD patients. Here, we summarized the results of treatment with satralizumab of 16 patients (14 men and 2 women), aged 13—69 years. Duration of therapy was 9 to 41 week. The first experience of using satralizumab in the Russian Federation in the small group of patients does not yet allow us to draw conclusions about the efficacy due to the short follow-up period. It can be concluded that the safety profile of satralizumab is consistent with the results obtained in international clinical trials. The experience gained in the ongoing program allows us to conclude that satralizumab is a valuable and convenient therapeutical option for seropositive for anti-AQP4-antibodies patients with NMOSD.

Keywords:

satralizumab
neuromyelitis optica
neuromyelitis optica spectrum disorder

Authors:

Prakhova L.N.

N. Bechtereva Institute of the Human Brain

Krasnov V.S.

Pavlov First St. Petersburg State Medical University

Kasatkin D.S.

Yaroslavl State Medical University

Korobko D.S.

State Novosibirsk Regional Clinical Hospital;
Novosibirsk State Medical University

Received:

26.05.2022

Accepted:

02.06.2022

Close metadata

References:

  1. Whittam D, Wilson M, Hamid S, et al. What’s new in neuromyelitis optica? A short review for clinical neurologist. J Neurol. 2017;264(11):2330-2344. https://doi.org/10.1007/s00415-017-8445-8
  2. Ma X, Kermode AG, Hu X, Qiu W. NMOSD acute attack: Understanding, treatment and innovative treatment prospect. J Neuroimmunol. 2020;348:577387. https://doi.org/10.1016/j.jneuroim.2020.577387
  3. Palace J, Lin DY, Zeng D, et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain. 2019;142;1310-1323. https://doi.org/10.1093/brain/awz054
  4. Weinshenker BG, Wingerchuk DM Neuromyelitis spectrum disorders. Mayo Clin Proc. 2017;92(4):663-679.  https://doi.org/10.1016/j.mayocp.2016.12.014
  5. Regulatory workshop on clinical trials designs in neuromyelitis optica spectrum disorders (NMOSD) Report of EMA workshop 10 October 2014 London, 16 June 2015 EMA/CHMP/SAWP/712652/2014 Product Development and Scientific Support Department.
  6. Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021;20(1):60-67.  https://doi.org/10.1016/s1474-4422(20)30392-6
  7. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17(8):1019-1032. https://doi.org/10.1111/j.1468-1331.2010.03066.x
  8. Trebst C, Jarius S, Berthele A, et al. Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014;34:261:1-16.  https://doi.org/10.1007/s00415-013-7169-7
  9. Kim SH, Kim W, Park MS, et al. Efficacy and Safety of Mitoxantrone in Patients With Highly Relapsing Neuromyelitis Optica. Archives of Neurology. 2011;68(4):473-480.  https://doi.org/10.1001/archneurol.2010.322
  10. Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014;71(3):324-330.  https://doi.org/10.1001/jamaneurol.2013.5699
  11. Nikoo Z, Badihian S, Shaygannejad V, et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017;264(9):2003-2009. https://doi.org/10.1007/s00415-017-8590-0
  12. Gao F, Chai B, Gu C, et al. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurology. 2019;19(1):36-39.  https://doi.org/10.1186/s12883-019-1261-2
  13. Ciron J, Audoin B, Bourre B, et al. NOMADMUS group, under the aegis of OFSEP, SFSEP. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Rev Neurol (Paris). 2018;174(4):255-264.  https://doi.org/10.1016/j.neurol.2017.11.005
  14. Novi G, Bovis F, Capobianco M, et al. iMUST group. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2019;36:101430. https://doi.org/10.1016/j.msard.2019.101430
  15. Contentti EC, Rojas JI, Cristiano E, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Multiple Sclerosis and Related Disorders. 2020;45:102428. https://doi.org/10.1016/j.msard.2020.102428
  16. Perumal JS, Kister I, Howard J, Herbert J. Disease exacerbation after rituximab induction in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;2:e61.  https://doi.org/10.1212/nxi.0000000000000061
  17. Marcinnò A, Marnetto F, Valentino P, et al. Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2018;13:5(6):e498. https://doi.org/10.1212/nxi.0000000000000498
  18. Ringelstein M, Ayzenberg I, Harmel J, et al. Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72(7):756-763.  https://doi.org/10.1001/jamaneurol.2015.0533
  19. Zhang C, Zhang M, Qiu W, et al. TANGO Study Investigators. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder: an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19(5):391-401.  https://doi.org/10.1016/S1474-4422(20)30070-3
  20. Prescribing information for medicinal product Enspryng. Ministry of Health of Russian Federation, LP-007335-300821. Accessed 24 May 2022. (In Russ.). https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=a0b786c6-1603-463c-8fd0-c203a35574a4&t=
  21. Tramboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disoder: a randomised, double-blind, multicentre, placebo-conroled phase 3 trial. Lancet Neurol. 2020;19:402-412.  https://doi.org/10.1016/s1474-4422(20)30078-8
  22. Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:2114-2124. https://doi.org/10.1056/nejmoa1901747
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.